Biomet BMET on Nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomet BMET on Nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mact who wrote (57)	3/22/2002 10:08:51 AM
From: mact	of 62

bought in this morning...this is a quality company...good grwoth...nice oppurtunity to get in this am. Biomet (BMET: news, chart, profile) reported a third-quarter profit of $61.7 million, or 23 cents a share, beating the year-ago per share profit of 21 cents a share. On average, analysts expected a profit of about 24 cents a share. Sales rose to $304.6 million, compared with $267 million. The increase in sales was attributed to strong growth in its reconstructive, spinal and other product lines. J.P. Morgan H&Q cut its rating to 'long-term buy.'

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next